Loading...
Bilateral Trade Intelligence · $29.5M Total Trade · 69 Exporters · 136 Buyers · DGFT Verified · Updated March 2026
India exported $29.5M worth of pharmaceutical formulations to Belarus across 2,821 verified shipments, sourced from 69 Indian exporters supplying 136 Belarus buyers. The top exporters are DR.REDDY'S LABORATORIES LTD ($9.7M) and IPCA LABORATORIES LIMITED ($5.1M). The leading products are Dolutegravir ($246K). Average shipment value: $10.5K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Efavir 600 MG Tablets (efavirenz) | $4.0M | 13.4% |
| 2 | Angricold Granules (blackcurrant) Batch | $960.5K | 3.3% |
| 3 | Angricold Granules (lemon Flavor) Batch | $917.6K | 3.1% |
| 4 | Ibuclin Tablets 400/325 MG (n10) (78540x10=785400 ) | $424.1K | 1.4% |
| 5 | Jocet Syrup 100 ML Bel Exp (pet Bottle) | $378.1K | 1.3% |
| 6 | Ketorol Tablets 10mg (n20) =14664x20=293280 | $343.1K | 1.2% |
| 7 | Ketrol Insta 10mg (n20) (10350x20=207000nos) | $322.9K | 1.1% |
| 8 | Myhep Dvir Dacl Sofo Tablets 60 400mg 28bt My En Fr Packs 15996 | $319.9K | 1.1% |
| 9 | Ketorol Tablets 10mg (n20) (12096x20=241920nos) | $315.7K | 1.1% |
| 10 | Cetrine Tablets 10mg N10 | $306.2K | 1.0% |
| 11 | Telsartan 40mg Tablets (n28) =1280x28=35840 | $267.4K | 0.9% |
| 12 | Medicines. Dolutegravir Sodium Dispersible Tablets 10 MG | $246.0K | 0.8% |
| 13 | Caberlin Tablets 0.5mg Contains Cabergolinepack: 2s Strip | $244.5K | 0.8% |
| 14 | Ketorol Tablets 10mg (n20) =10368x20=207360 | $242.6K | 0.8% |
| 15 | Ketorol Tablets 10mg (n20) =9792x20=195840 | $229.1K | 0.8% |
India exports 18+ pharmaceutical formulations to Belarus with a combined trade value of $29.5M. Key products include Dolutegravir ($246K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 2,821 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Belarus, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Belarus buyers, regulatory requirements, and logistics for that specific product corridor. Products include Dolutegravir ($246K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
Historical evolution, India's market position, and recent developments
The pharmaceutical trade between India and Belarus has experienced steady growth since Belarus gained independence in 1991. In 2024, bilateral trade reached $85.34 million, with India's exports to Belarus totaling $64.83 million and imports amounting to $20.51 million. This positive trajectory reflects the strengthening economic ties and the expanding role of the pharmaceutical sector in bilateral relations.
A significant milestone occurred in 2016 when three joint ventures were established between Indian and Belarusian companies in the pharmaceutical sector, involving an investment of approximately $3 million by Indian firms. These collaborations have facilitated technology transfer, enhanced production capabilities, and improved access to essential medicines in Belarus.
India's pharmaceutical exports to Belarus have been a crucial component of the bilateral trade relationship. In 2024, India exported pharmaceutical products worth $17.82 million to Belarus, accounting for a significant portion of Belarus's total pharmaceutical imports. This underscores India's strategic importance as a supplier of high-quality, affordable medicines to Belarus, contributing to the diversification and resilience of Belarus's pharmaceutical supply chain.
69 Indian pharmaceutical companies export finished formulations to Belarus. Leading exporters include Dr.reddy's Laboratories Ltd, Ipca Laboratories Limited, Cipla Limited, Syren Healthcare. The top exporter accounts for 32.8% of total India–Belarus pharma exports. Source: Indian Customs (DGFT).
136 companies in Belarus import pharmaceutical formulations from India. Top buyers include State Enterprise Academpharm, Open Joint-stock Company "ekzon", Jfv Belinvestfarma, Firm Interfarmax. The largest buyer accounts for 13.4% of India–Belarus pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, several developments have influenced the India-Belarus pharmaceutical trade corridor. In April 2024, the Republican Unitary Enterprise "BelLekoCenter" in Belarus reached out to Indian pharmaceutical companies seeking 84 high-quality medicines, including treatments for breast cancer and rheumatoid arthritis. This initiative highlights Belarus's commitment to enhancing its healthcare provisions through international collaboration.
Additionally, in April 2024, BELPHARMPROM, the Pharmaceuticals Holding Company under Belarus's Ministry of Health, sought collaboration with Indian pharmaceutical companies to address the demand for essential medicines and explore opportunities for localizing finished dosage forms. These efforts aim to strengthen Belarus's pharmaceutical industry and ensure a steady supply of critical medications.
Furthermore, in December 2025, India's pharmaceutical exports reached $30.47 billion, marking a 9.4% increase from the previous year. This growth reflects India's expanding global footprint in the pharmaceutical sector, which may positively impact its trade relations with countries like Belarus.
These developments indicate a dynamic and evolving pharmaceutical trade relationship between India and Belarus, characterized by increased collaboration, strategic investments, and a shared commitment to improving healthcare outcomes.
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical exports to Belarus are predominantly concentrated in the antiretroviral (ARV) segment, particularly efavirenz-based formulations. Efavirenz 600 mg tablets, marketed under the brand name EFAVIR, constitute approximately 13.4% of the total export value, with three distinct packaging configurations accounting for $3.9 million. This dominance aligns with Belarus's ongoing efforts to combat HIV/AIDS, a significant public health challenge. The United Nations Development Programme (UNDP) has been actively supporting Belarus in strengthening its HIV prevention and treatment systems, including the provision of antiretroviral therapy.
The substantial export of efavirenz tablets underscores India's role in supplying essential HIV medications to Belarus, addressing the country's critical need for effective antiretroviral treatments.
Belarus's healthcare system is undergoing modernization, with a focus on enhancing the quality and accessibility of medical services. This transformation presents opportunities for Indian pharmaceutical exporters to introduce advanced therapies and specialized treatments. The rising prevalence of non-communicable diseases (NCDs), such as cardiovascular diseases, diabetes, and cancer, is driving demand for innovative medications. The World Health Organization (WHO) reports that NCDs account for over 80% of deaths in Belarus, with cardiovascular diseases being the leading cause. (eurohealthobservatory.who.int)
Additionally, the global trend towards biosimilars offers a promising avenue for Indian companies to provide cost-effective alternatives to expensive biologic drugs, aligning with Belarus's efforts to make healthcare more affordable.
Belarus is experiencing a significant burden from non-communicable diseases (NCDs), which account for over 80% of deaths, with cardiovascular diseases being the leading cause. (eurohealthobservatory.who.int) This high prevalence of NCDs, coupled with an aging population, is increasing the demand for pharmaceutical imports, particularly for chronic disease management. The government's commitment to improving public health, as evidenced by the integration of health into its sustainable development agenda, further drives the need for diverse and effective medical treatments.
These factors collectively create a robust demand for pharmaceutical products, presenting opportunities for Indian exporters to meet Belarus's evolving healthcare needs.
Tariff structure, trade agreements, IP and patent landscape
Belarus's Most-Favored-Nation (MFN) tariff rates for pharmaceutical products under Harmonized System (HS) codes 3003 and 3004 are not publicly disclosed. This lack of transparency complicates the assessment of duty structures for Indian pharmaceutical exports to Belarus. However, the absence of a Free Trade Agreement (FTA) between India and Belarus suggests that MFN rates are applicable. Typically, MFN tariffs are higher than preferential rates offered under FTAs, potentially impacting the competitiveness of Indian pharmaceutical products in the Belarusian market.
The absence of preferential duty rates under any existing trade agreements further underscores the reliance on standard MFN tariffs for Indian pharmaceutical exports to Belarus. This scenario may necessitate strategic pricing and market positioning by Indian exporters to maintain competitiveness.
As of March 2026, there is no Free Trade Agreement (FTA) between India and Belarus. However, on September 15, 2025, India and the Eurasian Economic Union (EAEU), which includes Belarus, signed a binding framework to initiate negotiations for a free-trade agreement. This development could potentially lead to preferential trade terms for Indian pharmaceutical exports to Belarus in the future. (law.asia)
Belarus's intellectual property (IP) framework, including patent provisions, data exclusivity, and compulsory licensing, is not extensively documented in publicly available sources. This lack of transparency poses challenges for Indian pharmaceutical companies seeking to navigate the Belarusian market, particularly concerning the importation of generic drugs. Without clear information on IP regulations, Indian exporters may face uncertainties regarding patent infringements, data protection, and the potential for compulsory licensing, which could affect market entry strategies and product pricing.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from India to Belarus primarily utilize both sea and air transport, each offering distinct advantages. Sea freight, though cost-effective, is generally slower, with transit times from major Indian ports to Belarusian ports averaging 30 to 40 days. Air freight, while more expensive, significantly reduces transit times, typically ranging from 7 to 10 days. The choice between these modes depends on factors such as shipment urgency, cost considerations, and the nature of the pharmaceutical products.
Recent disruptions in the Red Sea have impacted global shipping routes, potentially affecting sea freight schedules and costs. Such disruptions can lead to longer transit times and increased freight rates due to the need for alternative routing. It's crucial for logistics planners to monitor these developments and adjust shipping strategies accordingly to maintain supply chain efficiency.
In India, key export ports handling pharmaceutical shipments include Delhi Air, Sahar Air, and Sahar Air Cargo Acc (INBOM4). Delhi Air accounts for 17.8% of exports, Sahar Air 25.1%, and Sahar Air Cargo Acc 15.5%. These ports are equipped with facilities suitable for handling pharmaceutical products, ensuring compliance with international shipping standards.
In Belarus, the primary import port is Minsk, which handles 86.4% of imports, followed by Riga at 1.1%. Minsk's infrastructure supports the efficient processing of pharmaceutical goods, facilitating timely customs clearance and distribution.
Maintaining the integrity of temperature-sensitive pharmaceutical formulations during transit is paramount. Cold chain logistics involves strict temperature control, typically between 2°C and 8°C, to preserve product efficacy. This requires the use of validated insulated packaging, real-time temperature monitoring devices, and adherence to Good Distribution Practice (GDP) guidelines. Compliance with these standards ensures that products remain safe and effective upon arrival.
Customs clearance in Belarus is a critical component of the cold chain process. Delays at customs can jeopardize product integrity, especially for temperature-sensitive items. Therefore, providing comprehensive documentation, including certificates of analysis and proof of temperature control, is essential to facilitate smooth customs procedures and prevent potential spoilage or financial losses.
Market size, healthcare system, growth outlook
Belarus's pharmaceutical market is projected to reach a revenue of approximately $280.37 million by 2025, with an annual growth rate of 3.9%. The market is expected to continue expanding, with a compound annual growth rate (CAGR) of 4.61%, reaching $351.26 million by 2030. This growth is driven by increasing healthcare expenditures, a rising prevalence of chronic diseases, and a strong emphasis on domestic pharmaceutical production.
The Belarusian pharmaceutical market is characterized by a significant reliance on imported finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. In 2022, Belarus's total pharmaceutical imports were valued at $280.37 million, indicating a high import dependency. The market is also witnessing a gradual shift towards generic drugs, with generics projected to grow at a CAGR of 7.2% globally, driven by cost-containment measures and the expiration of patents.
Belarus operates a state-controlled healthcare system, with the government playing a significant role in regulating the pharmaceutical market. The government sets prices for medicines and provides subsidies for certain categories, aiming to ensure affordability and accessibility for the population. Additionally, Belarus has been implementing policies to promote local production of medicines, leading to the growth of domestic pharmaceutical companies.
The government also prioritizes pharmaceutical self-sufficiency through state-owned manufacturers and regulated pricing mechanisms. This approach has led to the expansion of essential medicines lists and guaranteed procurement, ensuring consistent and stable market demand.
The Belarusian pharmaceutical market presents significant opportunities for Indian exporters, particularly in the generic drug segment. With a projected CAGR of 7.2% for generics globally, Belarus is expected to follow this trend, increasing the demand for cost-effective generic medicines. Indian pharmaceutical companies, known for their robust generic drug manufacturing capabilities, can leverage this demand to expand their presence in Belarus.
In 2022, India exported finished pharmaceutical formulations to Belarus valued at $29.5 million, with 2,821 shipments from 69 Indian exporters to 136 Belarusian buyers. The top products included EFAVIR 600 MG TABLETS (EFAVIRENZ), ANGRICOLD GRANULES, and IBUCLIN TAB 400/325 MG, indicating a strong demand for both branded and generic formulations. The average shipment value was $10,000, suggesting a diverse range of products catering to various therapeutic areas.
The growth forecast for Indian pharmaceutical imports into Belarus from 2025 to 2028 is promising, aligning with the overall market expansion and the increasing demand for generic drugs. By focusing on high-demand therapeutic areas and maintaining competitive pricing, Indian exporters can strengthen their market position and contribute to meeting Belarus's healthcare needs.
Competing origins, India's edge, challenges and threats
Belarus's pharmaceutical market is supplied by a diverse array of countries, including China, European Union (EU) member states, domestic manufacturers, and other emerging economies. China and the EU are significant contributors, with the EU exporting approximately $643.64K worth of pharmaceutical products to Belarus in 2023, while China exported about $282.10K in the same year. Domestic production also plays a crucial role in meeting Belarus's pharmaceutical needs, though specific data on domestic market share is limited. Other emerging suppliers, such as Armenia, have a minimal presence, exporting only $0.58K worth of pharmaceutical products to Belarus in 2023. While precise market share comparisons are challenging due to data limitations, it is evident that India, China, and the EU are the primary suppliers to Belarus's pharmaceutical market.
India's pharmaceutical industry offers several competitive advantages in the Belarusian market. With a total export value of $29.5 million USD over 2,821 shipments from 2022 to 2026, India demonstrates a robust presence. The country's adherence to WHO-GMP standards ensures high-quality products, enhancing its reputation for reliability. Additionally, India's English-speaking workforce facilitates effective communication and collaboration. The broad portfolio of Indian pharmaceutical exporters, including major companies like Dr. Reddy's Laboratories Ltd., IPCA Laboratories Limited, and Cipla Limited, provides Belarusian buyers with a wide range of products to meet diverse medical needs.
Despite its strengths, India faces several challenges in the Belarusian pharmaceutical market. Regulatory tightening by Belarus's National Drug Regulatory Authority (WHO-GMP) may pose obstacles for Indian exporters, requiring compliance with stringent standards. Competition from China, which offers cost-effective products, and from EU manufacturers, known for their advanced technologies, intensifies the market rivalry. Additionally, perceptions regarding the quality of Indian pharmaceuticals may affect their acceptance among Belarusian consumers, necessitating continuous efforts to maintain and enhance product quality and brand reputation.
India exported pharmaceuticals worth $29.5M to Belarus across 2,821 verified shipments.
1. DR.REDDY'S LABORATORIES LTD — $9.7M. 2. IPCA LABORATORIES LIMITED — $5.1M. 3. CIPLA LIMITED — $4.0M. Total: 69 suppliers.
1. STATE ENTERPRISE ACADEMPHARM — $4.0M. 2. OPEN JOINT-STOCK COMPANY "EKZON" — $2.0M. 3. JFV BELINVESTFARMA — $1.9M. 136 buyers total.
1. Efavir 600 MG Tablets (efavirenz) ($4.0M, 13.4%); 2. Angricold Granules (blackcurrant) Batch ($960.5K, 3.3%); 3. Angricold Granules (lemon Flavor) Batch ($917.6K, 3.1%); 4. Ibuclin Tablets 400/325 MG (n10) (78540x10=785400 ) ($424.1K, 1.4%); 5. Jocet Syrup 100 ML Bel Exp (pet Bottle) ($378.1K, 1.3%)
Export: DELHI AIR, SAHAR AIR, SAHAR AIR CARGO ACC (INBOM4), AHEMDABAD ICD, DELHI AIR CARGO ACC (INDEL4). Import: MINSK, Minsk, RIGA, Riga, Mogilev.
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $29.5M corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$10.5K per consignment across 2,821 shipments.
69 Indian companies. Largest: DR.REDDY'S LABORATORIES LTD with $9.7M.
TransData Nexus covers 69 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 2,821 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
69 Exporters
136 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists